Learn More
In a prospective phase I/II trial, EMD 55,900, a murine monoclonal antibody (MAb) directed against EGF receptor, was administered at tumour recurrence to 16 patients previously treated with surgery,(More)
3061 Background: Monoclonal antibody EMD 72000 blocks ligand binding and inhibits EGFR activation and signal transduction. EGFR is overexpressed in up to 90% of pancreatic cancers. We studied safety(More)
  • 1